WASHINGTON — Two powerful Senate lawmakers laid out an unexpectedly ambitious plan to lower the price of prescription drugs Thursday.

It came as part of a highly anticipated health care package from Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), the duo that helms the Senate health committee that is widely respected for bipartisan health-policy work.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • These legislation proposals are just window dressing on the real issues affecting healthcare costs. Insurance companies have been the real drivers of these costs. Just look at the profit margins and the salaries and bonuses of their CEO’s compared to other industries.

  • They also need to include that PBMs must respond to MAC appeals within 72 hours and indicate how they arrived at the Mac price. Pharmacies should not have to sell prescriptions below cost

  • Spread pricing must be stopped and PBMs should reimburse all pharmacies same as their own pharmacies. Or PBMs and insurance companies should not have a right to own pharmacies because conflict of interest. Transparency is must, how PBMs do their business (corruption).

    • Pharma calls the PBM’s the Maffia of the drug industry! D.O.J never should have allowed CVS the drug chain to buy CAREMARK the PBM. Did they not see a conflict of interest or were they just stupid ??????

  • Interesting challenge for our legislators. Would this bill stay intact or get watered down to the point of being meaning less effort. Lobbyists will eat this in its raw form as a rare steak.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy